Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Expected, FDA Misses Fourth Consecutive Deadline For Releasing Draft QSR

Executive Summary

The US FDA’s internal deadline of October 2020 for putting out a draft of its retooled Quality System Regulation is the fourth it failed to meet. The agency has been harmonizing its decades-old QSR with ISO 13485:2016 for more than two years.

You may also be interested in...



FDA Misses Fifth Target Date For Issuing Draft Harmonized Quality System Reg

It’s yet another internal deadline missed by the US agency in publishing a draft of its overhauled Quality System Regulation, which is being harmonized with international quality systems standard ISO 13485.

FDA Official Confirms 2021 For Release Of Draft QSR, Asks For ‘Inclusive Comment Spectrum’

The US FDA’s Elizabeth Miller says the agency won’t release a draft of its revised Quality System Regulation until sometime next year. The FDA has been harmonizing its QSR with international quality systems standard ISO 13485:2016 since 2018.

Icy HHS/FDA Relations Could Complicate An Already Drawn-Out Quality System Reg Rewrite

A roundup of last month’s top US policy and regulation stories from Medtech Insight: the latest on the US FDA’s Quality System Regulation harmonization efforts; the FDA’s Bakul Patel talks the inevitable future of digital health; a Sanofi usability expert gives a peek at how the company’s conducting human factors studies in the age of COVID-19; and more.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel